Overview

higher_edPhase 4ketaminepsilocybinMDMAOtherDMT

Yale Program for Psychedelic Science — researching psilocybin for OCD, DMT safety and efficacy, and neural mechanisms of psychedelic compounds. Part of Yale School of Medicine's Department of Psychiatry.

Visit Website
0
Open Roles

Open Positions

No open positions at this time

Research Areas

Clinical Pipeline(57)

Terminated·N/A·ketamine

Role Of Non-Specific Effects in The Treatment of Depression With Esketamine

Pre and Post Treatment PresentationsDepressive Episode
Enrolling by Invitation·N/A·ketamine

Long Term Follow Up KET-PD

Cognitive Behavior Therapy (CBT)Parkinson's Disease
Completed·Phase 1·psilocybin

Psilocybin for the Treatment of Cluster Headache

0.143 mg/kg Psilocybin or 10 mg PsilocybinCluster Headache
Completed·N/A·ketamine

Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention

Cognitive Behavioral Therapy CBTDepression and Suicide
Recruiting·Phase 3·ketamine

PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study

Racemic ketamineDepression
Not Yet Recruiting·Early Phase 1·psilocybin

Psilocybin Microdosing on Cognition, Mood and Quality of Life

PsliocybinPsychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI
Completed·N/A·ketamine

Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant Depression

Cognitive behavioral therapy (CBT) and medicationDepressive Disorder, Major
Recruiting·Phase 2·ketamine

Imaging Depression in Parkinson's Disease

11C-UCB-JParkinson's Disease
Enrolling by Invitation·N/A·ketamine

Using Virtual Reality to Control the Audio-visual Inputs During Ketamine/Esketamine Treatment

Virtual realityDepression
Completed·Phase 1·ketamine

THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis

Active Delta-9-THCCannabis
Withdrawn·Phase 1·MDMA

The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD.

MDMAPost Traumatic Stress Disorder
Completed·Phase 1·Other

GABA-glutamate Interactions and Psychosis

iomazenilCognitive Dysfunction
Recruiting·N/A·ketamine

Imaging SV2A in Mood Disorders

KetamineMajor Depressive Disorder
Completed·Phase 2·ketamine

Ketamine Infusion for Obsessive-Compulsive Disorder

ketamineObsessive-compulsive Disorder
Terminated·Phase 2·ketamine

Ketamine in Borderline Personality Disorder

KetamineBorderline Personality Disorder
Completed·N/A·ketamine

PET Imaging of mGLuR5 With Drug Challenge

KetamineMajor Depressive Disorder
Recruiting·N/A·ketamine

The OBSERVE Protocol

SpravatoMajor Depression Disorder
Completed·Phase 1·psilocybin

Psilocybin for the Treatment of Migraine Headache

High Dose PsilocybinMigraine Headache
Withdrawn·Phase 2·ketamine

Compare the Effect of Propofol vs. "Ketofol" on Hemodynamic Stability During Induction of General Anesthesia

PropofolPatients With "ASA 3" Designation
Active, Not Recruiting·Phase 1·psilocybin

Effects of Repeated Psilocybin Dosing in OCD

PsilocybinObsessive-Compulsive Disorder
Terminated·Phase 2·ketamine

Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy

Ketamine infusionMajor Depressive Disorder
Not Yet Recruiting·Phase 2·psilocybin

Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain

Psilocybin 10 mgChronic Low Back Pain (CLBP)
Withdrawn·Phase 2·ketamine

Trial of Ketamine and Lithium Therapy in Bipolar Depression

PlaceboBipolar Depression
Recruiting·Phase 1·ketamine

Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response

KetamineDepressive Disorder, Major
Recruiting·N/A·psilocybin

Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics

Serotonergic PsychedelicOCD
Completed·Early Phase 1·ketamine

Ketamine Infusion for Social Anxiety Disorder

KetamineSocial Anxiety Disorder
Recruiting·Phase 1·psilocybin

Open-Label Psilocybin Study in Transdiagnostic Population

PsilocybinTransdiagnostic
Active, Not Recruiting·Phase 1·psilocybin

Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder

Low Dose PsilocybinMajor Depressive Disorder
Recruiting·Phase 1·psilocybin

Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)

PsilocybinOpioid Use Disorder
Completed·N/A·ketamine

The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects

GuanfacineNMDA Receptor Function
Recruiting·Phase 2·ketamine

Enhancing Week-long Psychological Treatment for PTSD With Ketamine

KetaminePosttraumatic Stress Disorder
Recruiting·Phase 2·MDMA

MDMA in Borderline Personality Disorder

MDMABorderline Personality Disorder
Recruiting·Early Phase 1·psilocybin

Mechanistic Studies of Psilocybin in Headache Disorders

PsilocybinMigraine
Completed·Phase 1·ketamine

Ketamine for Low Mood States in the ER

ketamineDepression
Completed·Phase 1·psilocybin

Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.

Psilocybin (0.25mg/kg)Obsessive-Compulsive Disorder
Completed·Early Phase 1·ketamine

Examining The Effect Of Ketamine On Glutamate/Glutamine Cycling

KetamineDepression
Completed·N/A·ketamine

Ketamine/Placebo Family History Positive Study

Ketamine and PlaceboAlcoholism
Terminated·Phase 2·ketamine

Intensive 7-day Treatment for PTSD Combining Ketamine With Exposure Therapy

KetaminePosttraumatic Stress Disorder
Terminated·Phase 1·ketamine

The Sustained Effects of Ketamine

KetamineMental Disorders
Completed·Phase 2·ketamine

Ketamine for the Treatment of Depression in Parkinson's Disease

Ketamine InfusionParkinson's Disease
Completed·Phase 1·ketamine

Parallel Effects of Schizophrenia and N-methyl-D-aspartate (NMDA) Antagonism

ketamineSchizophrenia
Completed·Phase 1·ketamine

Cognitive Behavioral Therapy in Prolonging the Antidepressant Effects of Intravenous Ketamine

KetamineDepression
Completed·Early Phase 1·ketamine

Characterizing Clinical and Pharmacological Neuroimaging Biomarkers

MRICognitive Impairment
Active, Not Recruiting·Phase 1·DMT

Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans

0.1 mg/kg Dimethyltryptamine (DMT)Major Depressive Disorder
Completed·Phase 2·ketamine

Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects

KetamineDepression
Recruiting·Phase 2·ketamine

The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects

Perampanel 6 MGDepressive Disorder
Not Yet Recruiting·Early Phase 1·psilocybin

Psilocybin as a Treatment for Chronic Pain in Smokers

Psilocybin (drug)Smokers With Chronic Pain
Terminated·Phase 2·ketamine

Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine

Ketamine InfusionAdolescent Suicide
Completed·Phase 4·ketamine

Ketamine Infusion for Adolescent Depression and Anxiety

KetamineMajor Depressive Disorder
Completed·Phase 1·psilocybin

Repeat Dosing of Psilocybin in Migraine Headache

PsilocybinMigraine Headache
Completed·Phase 1·ketamine

N-acetylcysteine and NMDA Antagonist Interactions

N-acetylcysteine and ketamineCognitive Dysfunction
Completed·Phase 1·ketamine

Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial

KetamineDepressive Disorder, Major
Completed·Phase 1·ketamine

Ketamine for Depression and Alcohol Dependence

Ketalar (ketamine)Depression
Terminated·Phase 1·psilocybin

Effects of Psilocybin in Concussion Headache

Placebo oral capsulePost-Traumatic Headache
Completed·Phase 1·ketamine

Nicotinic Modulation of Schizophrenia-like Information Processing Deficits in Healthy Subjects

KetamineHealthy Subjects
Recruiting·Phase 1·DMT

The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)

0.3mg/kg/min Dimethyltryptamine + Normal Saline infusionAlcohol Use Disorder (AUD)
Completed·Phase 1·ketamine

Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects

Ketamine and Org 25935Healthy